Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

Takashi Kumagai, Eri Matsuki, Koiti Inokuchi, Kazuteru Ohashi, Atsushi Shinagawa, Jin Takeuchi, Chikashi Yoshida, Shinichiro Okamoto, Hisashi Wakita, Yasuji Kozai, Yukari Shirasugi, Shin Fujisawa, Osamu Iwase, Shingo Yano, Kaichi Nishiwaki, Koji Oba, Junichi Sakamoto, Hisashi Sakamaki

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Lymphocytosis in response to dasatinib for chronic myelogenous leukemia (CML) may be associated with favorable response. However, it occurs at varying times and in a limited subset of patients. To identify early clinical markers for favorable responses applicable to all patients with or without lymphocytosis, we prospectively analyzed lymphocyte profiles of 50 Japanese CML patients treated with dasatinib after intolerance/resistance to imatinib. Although absolute lymphocyte counts did not differ significantly until 3 months between patients with complete molecular response (CMR) at 12 months and those without it, relative increases in lymphocyte compared with baselines differed significantly from 1 month. Patients with relative lymphocyte counts >150% at 1 month or >200% at 3 months had higher CMR rates at 12 months than others (57.9 vs. 23.3%, P = 0.015, and 76.5 vs. 16.1%, P < 0.0001, respectively). A relative increase in lymphocyte subset of CD57+CD14-, CD8+T, or NK cells >200% at 1 month was also significantly associated with a higher CMR rate. There were significant negative correlations between relative lymphocyte increases and BCR/ABL transcript levels. CD57 +CD14- cells were a highly specific focus of proliferation. Relative increases in lymphocyte count and its subsets from 1 month are reliable early markers of favorable responses to dasatinib.

Original languageEnglish
Pages (from-to)41-52
Number of pages12
JournalInternational Journal of Hematology
Volume99
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Leukemia, Myeloid, Chronic Phase
Lymphocytes
Lymphocyte Count
Lymphocytosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Biomarkers
Dasatinib

Keywords

  • CML
  • Dasatinib
  • Lymphocytosis

ASJC Scopus subject areas

  • Hematology

Cite this

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. / Kumagai, Takashi; Matsuki, Eri; Inokuchi, Koiti; Ohashi, Kazuteru; Shinagawa, Atsushi; Takeuchi, Jin; Yoshida, Chikashi; Okamoto, Shinichiro; Wakita, Hisashi; Kozai, Yasuji; Shirasugi, Yukari; Fujisawa, Shin; Iwase, Osamu; Yano, Shingo; Nishiwaki, Kaichi; Oba, Koji; Sakamoto, Junichi; Sakamaki, Hisashi.

In: International Journal of Hematology, Vol. 99, No. 1, 2014, p. 41-52.

Research output: Contribution to journalArticle

Kumagai, T, Matsuki, E, Inokuchi, K, Ohashi, K, Shinagawa, A, Takeuchi, J, Yoshida, C, Okamoto, S, Wakita, H, Kozai, Y, Shirasugi, Y, Fujisawa, S, Iwase, O, Yano, S, Nishiwaki, K, Oba, K, Sakamoto, J & Sakamaki, H 2014, 'Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia', International Journal of Hematology, vol. 99, no. 1, pp. 41-52. https://doi.org/10.1007/s12185-013-1483-9
Kumagai, Takashi ; Matsuki, Eri ; Inokuchi, Koiti ; Ohashi, Kazuteru ; Shinagawa, Atsushi ; Takeuchi, Jin ; Yoshida, Chikashi ; Okamoto, Shinichiro ; Wakita, Hisashi ; Kozai, Yasuji ; Shirasugi, Yukari ; Fujisawa, Shin ; Iwase, Osamu ; Yano, Shingo ; Nishiwaki, Kaichi ; Oba, Koji ; Sakamoto, Junichi ; Sakamaki, Hisashi. / Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. In: International Journal of Hematology. 2014 ; Vol. 99, No. 1. pp. 41-52.
@article{38c3d97cfc7c4dbf83391de18d9e2ee5,
title = "Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia",
abstract = "Lymphocytosis in response to dasatinib for chronic myelogenous leukemia (CML) may be associated with favorable response. However, it occurs at varying times and in a limited subset of patients. To identify early clinical markers for favorable responses applicable to all patients with or without lymphocytosis, we prospectively analyzed lymphocyte profiles of 50 Japanese CML patients treated with dasatinib after intolerance/resistance to imatinib. Although absolute lymphocyte counts did not differ significantly until 3 months between patients with complete molecular response (CMR) at 12 months and those without it, relative increases in lymphocyte compared with baselines differed significantly from 1 month. Patients with relative lymphocyte counts >150{\%} at 1 month or >200{\%} at 3 months had higher CMR rates at 12 months than others (57.9 vs. 23.3{\%}, P = 0.015, and 76.5 vs. 16.1{\%}, P < 0.0001, respectively). A relative increase in lymphocyte subset of CD57+CD14-, CD8+T, or NK cells >200{\%} at 1 month was also significantly associated with a higher CMR rate. There were significant negative correlations between relative lymphocyte increases and BCR/ABL transcript levels. CD57 +CD14- cells were a highly specific focus of proliferation. Relative increases in lymphocyte count and its subsets from 1 month are reliable early markers of favorable responses to dasatinib.",
keywords = "CML, Dasatinib, Lymphocytosis",
author = "Takashi Kumagai and Eri Matsuki and Koiti Inokuchi and Kazuteru Ohashi and Atsushi Shinagawa and Jin Takeuchi and Chikashi Yoshida and Shinichiro Okamoto and Hisashi Wakita and Yasuji Kozai and Yukari Shirasugi and Shin Fujisawa and Osamu Iwase and Shingo Yano and Kaichi Nishiwaki and Koji Oba and Junichi Sakamoto and Hisashi Sakamaki",
year = "2014",
doi = "10.1007/s12185-013-1483-9",
language = "English",
volume = "99",
pages = "41--52",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

AU - Kumagai, Takashi

AU - Matsuki, Eri

AU - Inokuchi, Koiti

AU - Ohashi, Kazuteru

AU - Shinagawa, Atsushi

AU - Takeuchi, Jin

AU - Yoshida, Chikashi

AU - Okamoto, Shinichiro

AU - Wakita, Hisashi

AU - Kozai, Yasuji

AU - Shirasugi, Yukari

AU - Fujisawa, Shin

AU - Iwase, Osamu

AU - Yano, Shingo

AU - Nishiwaki, Kaichi

AU - Oba, Koji

AU - Sakamoto, Junichi

AU - Sakamaki, Hisashi

PY - 2014

Y1 - 2014

N2 - Lymphocytosis in response to dasatinib for chronic myelogenous leukemia (CML) may be associated with favorable response. However, it occurs at varying times and in a limited subset of patients. To identify early clinical markers for favorable responses applicable to all patients with or without lymphocytosis, we prospectively analyzed lymphocyte profiles of 50 Japanese CML patients treated with dasatinib after intolerance/resistance to imatinib. Although absolute lymphocyte counts did not differ significantly until 3 months between patients with complete molecular response (CMR) at 12 months and those without it, relative increases in lymphocyte compared with baselines differed significantly from 1 month. Patients with relative lymphocyte counts >150% at 1 month or >200% at 3 months had higher CMR rates at 12 months than others (57.9 vs. 23.3%, P = 0.015, and 76.5 vs. 16.1%, P < 0.0001, respectively). A relative increase in lymphocyte subset of CD57+CD14-, CD8+T, or NK cells >200% at 1 month was also significantly associated with a higher CMR rate. There were significant negative correlations between relative lymphocyte increases and BCR/ABL transcript levels. CD57 +CD14- cells were a highly specific focus of proliferation. Relative increases in lymphocyte count and its subsets from 1 month are reliable early markers of favorable responses to dasatinib.

AB - Lymphocytosis in response to dasatinib for chronic myelogenous leukemia (CML) may be associated with favorable response. However, it occurs at varying times and in a limited subset of patients. To identify early clinical markers for favorable responses applicable to all patients with or without lymphocytosis, we prospectively analyzed lymphocyte profiles of 50 Japanese CML patients treated with dasatinib after intolerance/resistance to imatinib. Although absolute lymphocyte counts did not differ significantly until 3 months between patients with complete molecular response (CMR) at 12 months and those without it, relative increases in lymphocyte compared with baselines differed significantly from 1 month. Patients with relative lymphocyte counts >150% at 1 month or >200% at 3 months had higher CMR rates at 12 months than others (57.9 vs. 23.3%, P = 0.015, and 76.5 vs. 16.1%, P < 0.0001, respectively). A relative increase in lymphocyte subset of CD57+CD14-, CD8+T, or NK cells >200% at 1 month was also significantly associated with a higher CMR rate. There were significant negative correlations between relative lymphocyte increases and BCR/ABL transcript levels. CD57 +CD14- cells were a highly specific focus of proliferation. Relative increases in lymphocyte count and its subsets from 1 month are reliable early markers of favorable responses to dasatinib.

KW - CML

KW - Dasatinib

KW - Lymphocytosis

UR - http://www.scopus.com/inward/record.url?scp=84899098640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899098640&partnerID=8YFLogxK

U2 - 10.1007/s12185-013-1483-9

DO - 10.1007/s12185-013-1483-9

M3 - Article

VL - 99

SP - 41

EP - 52

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -